- Home
- PHGE vs IMRN Comparison
PHGE vs IMRN Comparison
Compare PHGE & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- IMRN
- Stock Information
- Founded
- PHGE 2015
- IMRN 1994
- Country
- PHGE Israel
- IMRN Australia
- Employees
- PHGE N/A
- IMRN N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- PHGE Health Care
- IMRN Health Care
- Exchange
- PHGE Nasdaq
- IMRN Nasdaq
- Market Cap
- PHGE 13.3M
- IMRN 15.0M
- IPO Year
- PHGE N/A
- IMRN N/A
- Fundamental
- Price
- PHGE $0.96
- IMRN $1.90
- Analyst Decision
- PHGE Strong Buy
- IMRN Strong Buy
- Analyst Count
- PHGE 2
- IMRN 1
- Target Price
- PHGE $13.50
- IMRN $5.00
- AVG Volume (30 Days)
- PHGE 48.8K
- IMRN 4.7K
- Earning Date
- PHGE 04-02-2025
- IMRN 03-03-2025
- Dividend Yield
- PHGE N/A
- IMRN N/A
- EPS Growth
- PHGE N/A
- IMRN N/A
- EPS
- PHGE N/A
- IMRN N/A
- Revenue
- PHGE N/A
- IMRN $3,271,194.00
- Revenue This Year
- PHGE N/A
- IMRN N/A
- Revenue Next Year
- PHGE N/A
- IMRN N/A
- P/E Ratio
- PHGE N/A
- IMRN N/A
- Revenue Growth
- PHGE N/A
- IMRN 171.67
- 52 Week Low
- PHGE $0.48
- IMRN $1.65
- 52 Week High
- PHGE $8.55
- IMRN $5.96
- Technical
- Relative Strength Index (RSI)
- PHGE 65.22
- IMRN 43.76
- Support Level
- PHGE $0.87
- IMRN $1.89
- Resistance Level
- PHGE $0.99
- IMRN $2.05
- Average True Range (ATR)
- PHGE 0.08
- IMRN 0.08
- MACD
- PHGE 0.01
- IMRN -0.02
- Stochastic Oscillator
- PHGE 89.20
- IMRN 3.85
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.